Long-term EAP data confirms CS1’s safety

Cereno Scientific has reported encouraging initial observations from the 12-month Expanded Access Program (EAP), reinforcing CS1’s favourable safety and tolerability profile across longer-term use. While based on a small dataset (n=10; six completing 12 months), we view the findings as supportive of the upcoming Phase IIb plans,while also contributing to de-risking of the regulatory pathway and supporting ongoing partnering discussions. This is particularly relevant in pulmonary arterial hypertension, where current therapies, including vasodilators (in particular prostacyclins) and newer agents such as activin signalling inhibitors (such as Winrevair), are often limited by tolerability, affecting compliance and treatment persistence. Fur...